Facultad de Medicina (FM)
Centro académico
University of Innsbruck
Innsbruck, AustriaPublicaciones en colaboración con investigadores/as de University of Innsbruck (75)
2024
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
European Journal of Cancer, Vol. 202
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
Journal of Hepatology
-
L-serine treatment in patients with GRIN-related encephalopathy: A phase 2A, non-randomized study
Brain, Vol. 147, Núm. 5, pp. 1653-1666
-
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
American Journal of Hematology
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies
Journal of the American Heart Association, Vol. 12, Núm. 12, pp. e027657
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 188, pp. 131-139
-
Prognostic factors in patients with uterine sarcoma: The SARCUT study
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904
-
Social media ambassadors and collaboration with OncoAlert: A European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 964-970
-
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4419-4429
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months after a Diagnosis of COVID-19
Transplantation, Vol. 106, Núm. 5, pp. 1012-1023
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA
Nephrology Dialysis Transplantation, Vol. 37, Núm. 6, pp. 1140-1151
-
Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy
Scientific Reports, Vol. 12, Núm. 1
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease
New England Journal of Medicine, Vol. 387, Núm. 5, pp. 421-432